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Abstract
Background The last decade has seen the increasing use of biological medicines in combination with chemotherapy contain-
ing 5-luorouracil/oxaliplatin or irinotecan for the treatment of metastatic colorectal cancer (mCRC). These combinations 
have resulted in increased progression-free survival (PFS) in patients with mCRC; however, there are remaining concerns 
over the extent of their efect on overall survival (OS). Published studies to date suggest no major diferences between the 
three currently available monoclonal antibodies (MoAbs); however, there are diferences in costs. In addition, there is rising 
litigation in Brazil in order to access these medicines as they are currently not reimbursed.
Objective The aim was to investigate the comparative efectiveness and safety of three MoAbs (bevacizumab, cetuximab 
and panitumumab) associated with luoropyrimidine-based chemotherapy regimens and compared to luoropyrimidine-based 
chemotherapy alone in patients with mCRC, through an updated systematic review and meta-analysis of concurrent or non-
concurrent observational cohort studies, to guide authorities and the judiciary.
Method A systematic review and meta-analysis was performed based on cohort studies published in databases up to Novem-
ber 2017. Efectiveness measures included OS, PFS, post-progression survival (PPS), Response Evaluation Criteria In Solid 
Tumors (RECIST), response rate, metastasectomy and safety. The methodological quality of the studies was also evaluated.
Results A total of 21 observational cohort studies were included. There were statistically signiicant and clinically relevant 
beneits in patients treated with bevacizumab versus no bevacizumab mainly around OS, PFS, PPS and the metastasectomy 
rate, but not for the disease control rates. However, there was an increase in treatment-related toxicities and concerns with 
the heterogeneity of the studies.
Conclusion The results pointed to an advantage in favor of bevacizumab for OS, PFS, PPS, and metastasectomy. Although 
this advantage may be considered clinically modest, bevacizumab represents a hope for increased survival and a chance of 
metastasectomy for patients with mCRC. However, there are serious adverse events associated with its use, especially severe 
hypertension and gastrointestinal perforation, that need to be considered.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 9-018-0322-1) contains 
supplementary material, which is available to authorized users.
 * Brian Godman 
 Brian.Godman@strath.ac.uk; Brian.Godman@ki.se; 
Brian.Godman@liverpool.ac.uk
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Key Points 
The use of monoclonal antibodies (MoAbs) as a thera-
peutic option for metastatic colorectal cancer (mCRC) 
created expectations for greater overall survival as well 
as decreased toxicity and grade ≥ 3 adverse event com-
plications compared with cytotoxic chemotherapy.
The results of the studies included in this meta-analysis 
showed increased overall survival, progression-free 
survival and metastasectomy rate in patients with mCRC 
using MoAbs; however, there was great heterogeneity in 
the studies and severe adverse events.
It is important to assess the value and cost of interven-
tions for both irst- and second-line treatments when 
making choices. Marginal gains with associated high 
costs are diicult to justify within universal healthcare 
systems.
1 Introduction
Cancer is one of the leading causes of death worldwide, 
with more than 8.8 million deaths in 2015, up from 8.2 mil-
lion deaths in 2012 [1, 2], with breast, colorectal, lung, and 
stomach cancers the most commonly diagnosed cancers. 
The overall economic burden of cancer was estimated at 
US$1.6 trillion in 2010 and rising [2]. Colorectal cancer 
(CRC) continues to be a worldwide public health problem, 
with the number of new cases per year of CRC in 2012 at 
1.36 million [3, 4], corresponding to 10% of patients diag-
nosed with cancer in 2012. Overall, CRC is the third most 
common neoplasm in men and the second most common in 
women [5], with 694,000 deaths in 2012 [3].
CRC is a curable disease if diagnosed in early stages [6]. 
However, between 70 and 90% of CRC cases are currently 
diagnosed in advanced stages of the disease, resulting in 
initiatives including biomarkers to help identify patients 
earlier [5–8].
Since the 1990 s, luoropyrimidine-based chemotherapy 
(CT) (5-luorouracil [5-FU] or capecitabine) has been the 
principal treatment for CRC, with demonstrated beneits 
in overall survival (OS) [9, 10]. Irinotecan and oxaliplatin 
are widely used in combination with 5-FU and leucovorin 
(folinic acid) as irst- or second-line treatment for meta-
static CRC (mCRC) [11, 12], with studies demonstrating 
their addition as irst-line treatment improves median sur-
vival by 2–4 months [9, 11]. Whilst 5-FU and oxalipl-
atin have improved survival rates, this combination has 
resulted in a higher incidence of severe adverse events, 
however, with acceptable tolerability and maintenance of 
quality of life [11].
The use of molecular biological agents, monoclonal 
antibodies (MoAbs), in combination with 5-FU/oxaliplatin 
or irinotecan has become widespread to try and improve 
survival rates in patients with mCRC [6, 12–15]. However, 
the biological medicines have appreciably increased the 
cost of medicines with the high costs of MoAbs, often 
with limited health gain versus current standards. The high 
cost of biological medicines coupled with growing cancer 
prevalence rates have resulted in concerns for the future 
sustainability of healthcare systems [16–23].
The MoAbs used to treat patients with mCRC include 
cetuximab (CETUX) and panitumumab (PANIT) [5, 
14], which act on the epidermal growth factor receptor 
(EGFR), and bevacizumab (BEVA) [5], which acts on 
the vascular endothelial growth factor (VEGF) [5, 24]. 
They have all improved progression-free survival (PFS) 
in patients with mCRC; however, there have been con-
cerns expressed regarding the extent of their efectiveness 
with improving OS [14] and their cost-efectiveness [25, 
26]. Theoretically, payers of healthcare should not grant 
high prices for new cancer medicines that improve PFS 
but have limited or no improvement on OS, as this will 
afect available resources for other high-priority disease 
areas [27]. However, this has to be balanced against the 
emotive nature of the disease and the anxiety that patients 
with cancer have [28].
Improved targeting of high-priced biological medicines 
could potentially address these concerns. According to Rou-
gier and Mitry [10], MoAbs are restricted to patients without 
the Kirsten rat sarcoma viral oncogene (KRAS) and N-RAS 
oncogene mutations [29, 30]. Overall, approximately 45% of 
patients with mCRC with wild-type KRAS are resistant to 
treatment with CETUX [31]. Consequently, KRAS testing 
before CETUX can conserve resources [32–34].
The National Institute for Health and Care Excellence 
(NICE) in the UK currently recommends the use of CETUX 
and PANIT as an option for previously untreated anti-EGFR 
wild-type metastatic RAS in association with FOLFOX 
(folinic acid, 5-FU, oxaliplatin) or FOLFIRI (folinic acid, 
5-FU, irinotecan). BEVA is currently not recommended 
for use in the UK, either in combination with intravenous 
5-FU/folinic acid or with FOLFIRI for irst-line treatment 
of patients with metastatic carcinoma of the colon or rectum 
[35–37]. Australia’s Pharmaceutical Beneits Scheme does 
not mention BEVA for mCRC; however, it is indicated for 
epithelial ovarian, fallopian tube or primary peritoneal can-
cer [38, 39]. CETUX in combination with FOLFIRI has been 
approved by the Canadian Agency for Drugs and Technolo-
gies in Health for irst-line treatment in patients with mCRC 
and KRAS wild-type (KRAS-WT) oncogenes [40]. NICE do 
not recommend CETUX (monotherapy or combination CT), 
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BEVA (in combination with non-oxaliplatin CT) and PANIT 
(monotherapy) for mCRC after irst-line CT [41].
However, BEVA was considered by the  Avastin® Reg-
istry—Investigation of Efectiveness and Safety (ARIES) 
observational cohort study as a potential treatment for the 
mCRC in recent years [42].
A number of meta-analyses and other studies have shown 
no diference in health gain between these three MoAbs in 
mCRC patients [41–43]. Three systematic reviews, Hapani 
et al. [43], Lv et al. [44], and Rosa et al. [45], have also 
shown no additional clinical benefit with BEVA com-
pared with CT, i.e., FOLFORI or FOLFOX, or BEVA with 
CETUX or PANIT, in terms of increased eicacy or reduced 
side efects. However, a sub-study by Hurwitz et al. [46] 
conirmed the efectiveness of BEVA in the KRAS-WT sub-
group of mCRC patients. This compares with the meta-anal-
ysis of Wagner et al. [47], who evaluated ive randomized 
clinical trials (RCTs) with 3101 participants comparing 
BEVA versus no BEVA for irst-line CT, which showed 
signiicant beneits for OS or PFS in favor of BEVA-treated 
patients. We note though that in the no BEVA group, in addi-
tion to CT regimens, the authors included vatalanib (another 
VEGF inhibitor), which was not included in our review. In 
addition, there was a high incidence of grade 3 and 4 adverse 
events including hypertension, arterial thromboembolic 
events and gastrointestinal perforations in patients treated 
with BEVA [43, 47].
Currently, in the Brazilian health system (Sistema Único 
de Saúde [SUS]), BEVA, CETUX and PANIT can only 
be used and funded after successful litigation against the 
state, or 100% co-payment, since they are not incorporated 
into the health system. The Brazilian Health Technology 
Assessment Agency of SUS (Comissão Nacional de Incor-
poração de Tecnologias no SUS [CONITEC]) did not rec-
ommend the incorporation of CETUX for the management 
of mCRC in view of concerns with its price and limited 
health gain, and currently, BEVA and PANIT have not yet 
been evaluated for inclusion into SUS [48]. In view of this, 
successful litigation is the only means for patients to have 
these treatments funded within SUS. In the state of Minas 
Gerais (MG), public expenditure on BEVA, CETUX and 
PANIT as a result of successful litigation was approximately 
US$20 million between 2009 and 2016 (Fig. 1E in the elec-
tronic supplementary material). This is a concern as these 
monies are not available for cost-efective medicines in 
other high-priority disease areas. Currently, the ex-factory 
monthly treatment costs based on prices from Câmara de 
Regulação do Mercado de Medicamentos (CMED) Agência 
Nacional de Vigilância Sanitária (ANVISA) [49] are BEVA 
U$2897.90, CETUX US$6585.10 and PANIT US$3100.20. 
Consequently, CETUX is more expensive than BEVA by 
127% and more expensive than PANIT by 112%. PANIT is 
more expensive than BEVA by 6%.
Faced with the contradictory scenario regarding the use 
of MoAbs in mCRC, as well as considerable diferences 
in prices between these three and versus standard CT, the 
objective of this study was to evaluate the efectiveness 
and safety of BEVA, CETUX and PANIT in combination 
with or compared to luoropyrimidine-based CT alone in 
patients with mCRC, through an updated systematic review 
and meta-analysis with prospective or retrospective obser-
vational cohort studies. We believe the updated review will 
help people better understand the beneits and harms of the 
diferent treatments in heterogeneous populations in the ‘real 
world,’ relecting conditions in routine clinical practice [50, 
51]. This is important given the increasing costs of treat-
ments for cancer, increasing pressure on available resources 
[26, 27, 34, 52–54], and the extent of current litigation sur-
rounding these three MoAbs in Brazil.
2  Methods
This systematic review was based on the recommendations 
of the guidelines for Meta-analysis Of Observational Stud-
ies in Epidemiology (MOOSE) [55], with the protocol reg-
istered with the International Prospective Register of Sys-
tematic Reviews (PROSPERO) under no. CRD42016046613 
(http://www.crd.york.ac.uk/PROSP ERO).
2.1  Database and Search Strategy
The databases searched for potentially eligible studies 
included MEDLINE/PubMed (Medical Literature Analy-
sis and Retrieval System Online), LILACS (Latin Ameri-
can and Caribbean Health Science Literature), Cochrane 
Library, and EMBASE. All sources were searched until 
November 2017. We used various combinations of MeSH 
terms, including those relating to the disease, interventions, 
and study types (see the electronic supplementary mate-
rial, Table 1E). We supplemented this search with a manual 
search. In the manual search, we reviewed references in the 
annals of the Annual Meeting of the American Society of 
Clinical Oncology and the European Society for Medical 
Oncology between January 2014 and November 2017. In 
addition, we also manually searched the Journal of Clinical 
Oncology, the British Journal of Cancer, the Journal of the 
American Medical Association, and the World Journal of 
Gastroenterology, also for the period January 2014–Novem-
ber 2017.
We also searched the grey literature registered in the data 
bank of the Brazilian Digital Library of Theses and Dis-
sertations, the Digital Library of Theses and Dissertations 
of the University of São Paulo (USP), the Capes Theses 
Database, and the ProQuest Dissertation and Theses Data-
base, which included academic, government and conferences 
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publications, books and reports, and the Digital Library of 
Theses of the Federal University of Minas Gerais (UFMG).
2.2  Selection of Studies and Eligibility Criteria
We selected concurrent and non-concurrent observational 
studies of patients with mCRC. The studies compared the 
efectiveness and/or safety of BEVA, CETUX, and PANIT 
combined with FOLFIRI, FOLFOX, or luorouracil, leucov-
orin and oxaliplatin (FLOX), or luorouracil and leucovorin 
(5-FU/LV), or other combinations of luoropyrimidine-based 
CT versus BEVA, CETUX, and PANIT, or any CT scheme 
including fluoropyrimidine-based CT alone in patients 
undergoing treatment.
The inclusion criteria included studies published in Portu-
guese, English or Spanish; patients aged 18 years and older 
of both sexes; stage IV mCRC; life expectancy > 3 months; 
and wild-type or mutant KRAS.
Studies were excluded if they compared doses, inter-
vention methods, or clinical protocols; were reviews, case 
reports, or studies in animals; were in vitro, pharmacody-
namic and/or pharmacokinetic studies; were genetic and/or 
genomic studies; investigated other types of cancer; assessed 
concomitant therapies with MoAbs other than BEVA, 
CETUX, and PANIT; and included participants under the 
age of 18 years, or those who had less than 3-months of 
follow-up.
2.3  Selection of Studies and Data Collection
The studies found in the electronic databases were collected 
into a single database  (EndNote® software) in order to delete 
duplicates. The selection and inclusion of studies were per-
formed in two stages by two pairs of independent review-
ers (WS and PA, JS and MS). This included the analysis 
of titles/abstracts followed by the full texts. Disagreements 
were resolved by a third reviewer (VA). The characteristics 
of the patients, their treatment length, as well as efective-
ness and safety data were retrieved and incorporated into an 
Excel spreadsheet designed for this purpose and previously 
tested.
2.4  Assessment of Methodological Quality 
of Included Studies
We used the Newcastle-Ottawa scale to assess the methodo-
logical quality of the observational studies [55, 56]. In this 
scale, each study is assessed in three dimensions: selection 
of the study groups; comparability of groups; and the cal-
culation of any exposure or outcomes of interest. The total 
score can be up to nine stars, and studies with a score above 
six are considered to be of high quality.
The sources of funding for the identiied studies were 
examined for potential sources of bias. This is because the 
inluence of this on subsequent indings has been seen in 
previously conducted reviews [57–59]. Comments regard-
ing any conlicts of interest (COI), the source of inancing 
of the study, including whether funded by the manufac-
turer of any of the evaluated MoAbs, or whether any of 
the authors were related to the pharmaceutical industry, 
or received fees, were examined and documented. The 
possibility of publication bias was assessed using funnel 
plots [60] for the outcome if more than ten studies were 
involved.
2.5  Outcome Measures
The primary outcome measures considered were OS, PFS, 
and post-progression survival (PPS). The assessment of 
OS, measured by the time between diagnosis and death 
from any cause, is the most accepted method to assess the 
outcomes of cancer treatments, especially among payers of 
healthcare working with inite budgets in view of concerns 
linking PFS and other surrogate markers with OS in solid 
tumors [4, 24, 61–66]. American and European oncology 
groups also agree that OS should be the principal outcome 
measure in clinical studies [4, 62, 64], although PFS is 
also mentioned.
It is worth noting that PFS is used as a measure to assess 
a direct treatment efect on patients with metastatic can-
cer. However, PFS can be a concern when replacing OS, 
especially for funding decisions based on OS estimations 
in, for instance, cost/quality-adjusted life year calculations 
[67]. Having said this, PFS is validated and relevant to the 
patients. However, when used alone, it is not considered to 
be enough evidence of beneit to patients, which is exempli-
ied by recent guidance from the American Society of Clini-
cal Oncology [64]. For this reason, OS is recommended as 
a measure of efectiveness for new cancer medicines [65, 
68], with a signiicant efect on OS necessarily entailing a 
signiicant efect on PFS [66].
The secondary outcome measures were metastasectomy 
rates, response rates or disease control rate assessed by the 
Response Evaluation Criteria In Solid Tumors (RECIST) 
[69], and the occurrence of severe adverse events, consider-
ing only grade ≥ 3. The documentation of adverse events 
followed the Common Terminology Criteria for Adverse 
Events (CTCAE, version 4.0) of the National Institutes of 
Health (NIH) National Cancer Institute [70]. This describes 
and reports adverse events in a systematic way, providing a 
scale of severity for each adverse event ranging from grade 
1 up to grade 5, i.e., 1 = mild; 2 = moderate; 3 = severe; 
4 = extremely severe, life threatening; and 5 = death due to 
adverse events.
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2.6  Summary of Data and Statistical Analysis
The data from the studies were combined using the random 
efects model of the Review  Manager® software, version 
5.3. The results were presented by mean diference (MD) 
in months for continuous variables and expressed as rela-
tive risk for dichotomous variables, with a 95% conidence 
interval (CI). To estimate the magnitude of statistical incon-
sistency, we used the test I2 > 50% and a p value of < 0.10 
in the Chi-square test. Values above 75% were considered 
to have high heterogeneity [60]. A sensitivity analysis was 
conducted to assess the causes of heterogeneity, excluding 
one study at a time [60] and observing the changes in the I2 
and p values.
Due to the great variety of CT regimens based on luoro-
pyrimidines, we chose to construct the grouping of the forest 
graph by the similarity of the treatments.
In cases where it was not possible to carry out the meta-
analysis, a qualitative synthesis of the studies was performed 
as the heterogeneity of the measurement instruments and the 
data did not allow for quantitative synthesis.
3  Results
3.1  Search Results and Included Studies
We found a total of 2363 publications in the electronic 
databases. After excluding duplicates, 2175 articles were 
selected for analysis of the titles and abstracts, and 269 for 
thorough reading. After a full analysis of the articles, 21 
studies were inally included in the meta-analysis (see the 
electronic supplementary material, Fig. 2E).
3.2  General Characteristics of the Studies Included 
in the Meta‑Analysis
The 21 observational studies that were included in the meta-
analysis were of the cohort type. Seventeen of them had a 
non-concurrent design and four a concurrent design. The 
follow-up time ranged from 6 to 37 months; however, this 
information was not reported in eight studies [69–76]. The 
duration of the studies ranged from 36 months (3 years) to 
132 months (11 years); however, no information was given 
in two studies [78, 79]. Eight studies declared COI, nine 
studies declared having no COI, and three studies did not 
provide this information. With respect to funding, seven 
studies did not mention the sources of funding [71, 72, 76, 
80–83], seven declared having been funded by the pharma-
ceutical industry [42, 73, 75, 78, 84–86], and the other stud-
ies were funded through other sources.
Nine studies assessed treatment with BEVA versus vari-
ous CT regimens including fluoropyrimidine-based CT 
(i.e., including FOLFIRI, FOLFOX, and FLOX), four stud-
ies assessed BEVA versus CETUX, and only two studies 
compared CETUX versus PANIT. Five studies assessed 
treatment with BEVA during maintenance therapy, i.e., no 
BEVA beyond disease progression (no BBP) (BEVA vs no 
BBP) (Table 1).
3.3  Methodological Quality
Among the studies assessed for methodological quality, two 
studies [42, 84] obtained the maximum score of nine stars 
using the Newcastle-Ottawa scale, three scored eight stars, 
seven scored seven stars, eight studies scored six, and one 
study scored ive stars. As a result, the studies were seen 
overall as of moderate quality (Table 1). There was, though, 
asymmetry in the funnel plot for OS, suggesting publication 
bias (see the electronic supplementary material, Figs. 3E and 
4E).
3.4  Clinical Characteristics of the Patients 
in the Included Studies
To assess the comparative efectiveness and safety of the 
MoAbs (BEVA, CETUX, and PANIT) combined with CT 
or compared to only CT schemes, 10,180 participants were 
assessed in the 21 studies. The size of the studies ranged 
between 26 and 2526 patients.
With respect to the sociodemographic and clinical charac-
teristics of the patients in the studies, the patients’ mean ages 
ranged between 47 and 73 years and 40.5% were women. 
On average, according to data from ive studies, 54% of the 
patients had exhibited wild-type KRAS and 45% unknown 
KRAS. In 14 of the studies, the primary location of the 
tumor was in the colon versus the rectum or other sites, and 
this was seen in 75% of patients. For lymph nodal metasta-
ses, only four studies presented data, and these metastases 
occurred in 32% of patients. According to data collected 
from six studies, the proportion of liver and lung metastases 
was 56% and 29%, respectively. Seven studies presented data 
for primary tumor removal, with 72.5% of the patients hav-
ing undergone resection of their primary tumor. Regarding 
the rate of disease control, ive studies showed a 74% con-
trol rate, whereas, for progressive disease, this was 27% of 
patients according to the RECIST scale (Table 2).
3.5  Summary of the Data
BEVA was the most used MoAb in the largest number of 
studies that met the inclusion criteria. Due to the scarcity of 
comparative observational studies for PANIT and CETUX, 
we organized a comparison with a group called ‘with BEVA’ 
versus other therapeutic schemes that did not contain BEVA 
(no BEVA). From this group, we obtained ive intervention 
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subgroups (Table  3), namely (a) BEVA + CT versus 
CT alone without specification of the combination; (b) 
BEVA + FOLFIRI versus FOLFIRI; (c) BEVA + FOLFOX 
versus FOLFOX; (d) BEVA + CT versus CETUX + CT; 
and (e) BEVA versus no BBP (without BEVA maintenance 
beyond progression and maintenance of some CT scheme). 
Two arms were built, i.e., BEVA versus no BEVA, since it 
was not possible to compare CETUX versus PANIT since 
there were concerns with the key measurements used. In 
addition to inding only two studies [12, 75] with this com-
parison, the authors used the median as a measure of central 
tendency. This is diferent from the other arms, where means 
were used for comparative purposes, making it diicult to 
include this arm in the analysis.
3.6  Primary Outcomes
OS and PFS had been assessed in all the intervention sub-
groups described, and PPS had been assessed in only one 
intervention subgroup (BEVA vs no BBP) [42, 73, 81, 84, 
85].
3.6.1  Overall Survival
We included 16 studies on OS, with 11,094 participants. 
There were significant differences between the groups 
BEVA versus no BEVA [13, 42, 71, 73, 74, 77, 78, 81–87] 
(MD = 4.07; 95% CI 1.69–6.45; p < 0.001; I2 = 81%). How-
ever, when we look at the clusters of CT regimens separately, 
we note the following: there were no statistically signiicant 
diferences between the subgroups of BEVA + CT versus CT 
alone [13, 71, 78, 82] (MD = 2.83; 95% CI − 1.76 to 7.41; 
p = 0.23; I2 = 87%); BEVA + CT versus CETUX + CT [74, 
77, 86, 87] (MD = − 0.52; 95% CI − 7.7 to 6.67; p = 0.89; 
I2 = 0%) and BEVA + FOLFOX versus FOLFOX [13, 83] 
(MD = 8.63; 95% CI − 9.93 to 27.19; p = 0.36; I2 = 96%).
The subgroup BEVA + FOLFORI versus FOLFIRI [13] 
had been assessed in only one study, and the OS diference 
was not signiicant. The only signiicant diferences were 
in the subgroups BEVA versus no BBP [42, 73, 81, 83, 85] 
(MD = 4.89; 95% CI 1.91–7.87; I2 = 73%), favoring BEVA 
(Table 3; Fig. 1).
We performed heterogeneity tests taking into consid-
eration the grouping of the CT regimens (or FOLFIRI or 
FOLFOX). We noticed that there was a diference when we 
removed the studies that used FOLFOX in association with 
BEVA. The heterogeneity was reduced from I2 = 81% to 
I2 = 68%. The withdrawal of the two studies (Suenaga et al. 
[83] and Meyerhardt et al. [13]) using FOLFOX as the asso-
ciated CT in the comparison arms with BEVA reduced the 
heterogeneity; however, this did not signiicantly change the 
outcome of this meta-analysis.
When we undertook sensitivity analysis with the exclu-
sion of the study by Grothey et al. [85], in the BEVA versus 
Table 3  Outcomes evaluated in the meta-analysis: BEVA vs schemes without BEVA (no BEVA)
I2 > 50% and a p value of the Chi-square test < 0.10 indicate signiicant heterogeneity between the studies
BEVA bevacizumab, CETUX cetuximab, CI conidence interval, CT chemotherapy, FOLFIRI folinic acid, 5-luorouracil, irinotecan, FOLFOX 
folinic acid, 5-luorouracil, oxaliplatin, I2 heterogeneity, NA not applicable, no BBP no bevacizumab beyond progression, RECIST Response 
Evaluation Criteria In Solid Tumors
Outcomes Studies n (references) Participants Estimated efect [95% CI] (pvalue) I2 (%) p value
Overall survival (months) 16 [13, 42, 71, 73, 74, 77, 78, 81–87] 11,094 4.07 [1.69 to 6.45] (p < 0.001) 81 0.00001
BEVA + CT vs CT alone 4 [13, 71, 78, 82] 4842 2.83 [− 1.76 to 7.41] (p = 0.23) 87 0.00001
BEVA + FOLFIRI vs FOLFIRI 1 [13] 267 2.20 [− 4.43 to 8.83] (p = 0.52) NA NA
BEVA + FOLFOX vs FOLFOX 2 [13, 83] 1885 8.63 [− 9.93 to 27.19] (p = 0.36) 96 0.00001
BEVA + CT vs CETUX + CT 4 [74, 77, 86, 87] 547 − 0.52 [− 7.71 to 6.67] (p = 0.89) 0 0.99
BEVA vs no BBP 5 [42, 73, 81, 84, 85] 3553 4.89 [1.91 to 7.87] (p = 0.001) 73 0.005
Progression-free survival 
(months)
11 [42, 71, 74, 76, 78, 81–83, 87, 88] 3704 2.85 [0.74 to 4.96] (p < 0.008) 90 0.00001
BEVA + CT vs CT alone 4 [71, 78, 82, 88] 2405 2.21 [− 0.06 to 4.48] (p = 0.06) 70 0.002
BEVA + FOLFORI vs FOLFIRI 1 [76] 35 8.60 [7.52 to 9.68] (p < 0.00001) NA NA
BEVA + FOLFOX vs FOLFOX 2 [76, 83] 247 3.72 [− 1.53 to 8.96] (p = 0.16) 95 0.0001
BEVA + CT vs CETUX + CT 2 [74, 87] 315 2.00 [0.33 to 3.67] (p = 0.04) 0 0.67
BEVA vs no BBP 2 [42, 81] 702 1.65 [− 3.74 to 7.03] (p = 0.55) 92 0.0003
Post-progression survival 
(months)
3 [73, 84, 85] 2851 5.90 [2.59 to 9.21] (p = 0.0005) 82 0.004
BEVA vs no BBP 3 [73, 84, 85] 2851 5.90 [2.59 to 9.21] (p = 0.0005) 82 0.004
Disease control rate (RECIST) 5 [74, 77, 80, 83, 88] 571 1.05 [0.98 to 1.12] (p = 0.45) 10 0.18
Metastasectomy rate (%) 2 [71, 77] 1897 2.01 [1.44 to 2.81] (p < 0.0001) 0 0.87
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no BBP grouping, we noticed that the reduction in the 
heterogeneity of this grouping was reduced from I2 = 73% 
to I2 = 0%. The general heterogeneity was reduced from 
I2 = 68% to I2 = 59%, and there was no change in the clinical 
outcome direction, with a statistically signiicant diference 
between the interventions (p < 0.00001)
3.6.2  Progression‑Free Survival
We included 11 studies on PFS with 3704 participants. 
There were significant differences between the groups 
BEVA versus no BEVA (MD = 2.85; 95% CI 0.74–4.96; 
p = 0.008; I2 = 94%). We performed the sensitivity analyses 
in the intervention subgroups because of the high statistical 
heterogeneity (I2 = 94%; p < 0.00001) (Table 3; Fig. 2).
In this analysis, the individual exclusion of studies of any 
intervention group neither reduced the high heterogeneity 
nor changed the outcome. However, the combined exclusion 
of studies, namely Hurwitz et al. [42] with BEVA versus 
no BEVA, Varol et al. [76] with BEVA + FOLFOX versus 
FOLFOX, Varol et al. [76] with BEVA + FOLFIRI versus 
FOLFIRI, and Turan et al. [82] on BEVA versus CT, showed 
MD = 3.30, 95% CI 2.17–4.42, p < 0.00001, and I2 = 0%.
3.6.3  Post‑Progression Survival
For PPS, we included three studies with 2851 participants. 
These three studies only assessed the efect of BEVA ver-
sus the no BBP intervention subgroup [73, 84, 85]. It was 
noted that the results of the meta-analysis demonstrated a 
signiicant beneit in PPS for patients treated with BEVA 
Fig. 1  Overall survival forest plot
Comparative Effectiveness/Safety of Monoclonal Antibodies in Combination with CT for mCRC 
Fig. 2  Progression-free survival forest plot
Fig. 3  Post-progression survival forest plot
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(MD = 5.9; 95% CI 2.59–9.21; p = 0.0005) and high sta-
tistical heterogeneity (I2 = 82%; p = 0.004). In the sen-
sitivity analysis, the exclusion of the study conducted by 
Grothey et al. [84] indicated reduced heterogeneity (I2 = 0%; 
MD = 4.12; 95% CI 2.57–5.68; p < 0.00001) without chang-
ing the direction of the outcome (Table 3; Fig. 3).
3.7  Secondary Outcomes
For secondary outcomes, we analyzed 571 participants 
from ive studies on the response rate or disease control rate 
measured by the RECIST scale [74, 77, 80, 82] and 1897 
participants from two studies regarding the metastasectomy 
rate [71, 77].
In the meta-analysis, we assessed eight studies that had 
described severe adverse events [72, 77, 83–85, 88, 89] for 
safety, including hypertension, arterial thromboembolism, 
venous thromboembolism, gastrointestinal perforation, 
bleeding, diarrhea, neutropenia, and other severe adverse 
events (Table 4).
The meta-analyses that assessed the disease control rate 
[74, 77, 80, 83, 90] did not show any statistically signiicant 
diferences between BEVA and no BEVA interventions. The 
comparison revealed low heterogeneity (I2 = 10%; p = 0.18)
With respect to the metastasectomy rate [71, 77], 
there were statistically signiicant diferences for BEVA 
(p < 0.0001) in comparison to no BEVA intervention. The 
meta-analysis showed no heterogeneity (Fig. 4).
Regarding adverse events, there were no statistically sig-
niicant diferences between the interventions for arterial and 
venous thromboembolism, bleeding, diarrhea, neutropenia, 
and other severe adverse events (Table 4)
Table 4  Severe adverse events (grade ≥ 3)
CI conidence interval, GI gastrointestinal, I2 heterogeneity
Outcomes Studies n (references) Participants Estimated efect/[95% CI]/(p value) I2 (p value)
Hypertension 3 [76, 84, 85] 2436 1.36 [1.09–1.71] (p = 0.007) 2% (p = 0.36)
Arterial thromboembolism 4 [72, 81, 84, 85] 2948 0.89 [0.63–1.26] (p = 0.51) 0% (p = 0.81)
Venous thromboembolism 4 [13, 77, 81, 84] 4009 0.97 [0.82–1.13] (p = 0.66) 0% (p = 0.79)
GI Perforation 5 [13, 77, 81, 84, 85] 5182 1.89 [0.99–3.59] (p = 0.05) 17% (p = 0.31)
Bleeding 4 [77, 84, 85, 90] 2525 1.71 [0.80–3.65] (p = 0.17) 26% (p = 0.26)
Diarrhea 2 [77, 83] 371 0.63 [0.17–2.31] (p = 0.49) 0% (p = 0.49)
Neutropenia 2 [77, 83] 371 1.19 [0.90–1.58] (p = 0.22) 0% (p = 0.40)
Others events 4 [74, 83, 84, 90] 1565 1.27 [0.66–2.45] (p = 0.48) 8% (p = 0.35)
Fig. 4  Metastasectomy rate forest plot
Fig. 5  GI perforation forest plot. GI gastrointestinal
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With respect to gastrointestinal perforation (Fig. 5), we 
assessed ive studies with 5182 participants. There was a 
borderline statistical diference, with a relative risk of 1.89, 
95% CI 0.99–3.59, p = 0.05, and I2 = 17%. We performed 
a sensitivity analysis excluding the study conducted by 
Grothey et al. [84]. We obtained a relative risk of 2.48 (95% 
CI 1.36–4.53), p = 0.003, and I2 = 0%, favoring the risk of 
an event occurring with BEVA.
There were statistically signiicant diferences for hyper-
tension demonstrating the risk for this event with BEVA 
in comparison to no BEVA (p = 0.007). The meta-analysis 
indicated low heterogeneity (Fig. 6). Table 4 shows in detail 
the outcomes of severe adverse reactions comparing BEVA 
with no BEVA schemes.
3.8  Conlict of Interest
For the COI, we included nine studies with 8049 par-
ticipants. These nine studies evaluated the overall quality 
effect of the studies of the BEVA versus no BEVA [13, 
42, 71, 73, 74, 81, 83–85]. It was noted that the results 
of the meta-analysis demonstrated a significant differ-
ence in the COI subgroup for patients treated with BEVA 
(MD = 4.85; 95% CI 2.30–7.40; p = 0.0002) and high 
statistical heterogeneity (I2 = 74%, p = 0.004) (see the 
electronic supplementary material, Fig. 5E). The overall 
effect of the combined subgroups (COI and no COI) was 
also highly significant for patients treated with BEVA 
(p < 0.00001). Consequently, some of the studies may 
have been influenced by publication bias, as shown by 
funnel plots.
3.9  Quality of the Studies (Newcastle‑Ottawa Scale)
We included 19 studies with 9856 participants for BEVA 
versus no BEVA [13, 42, 71–74, 76–78, 80–87, 90]. There 
was a signiicant diference in the subgroup with a qual-
ity of seven or more stars for patients treated with BEVA 
(MD = 4.52; 95% CI 3.26–7.10; p < 0.00001) and a high sta-
tistical heterogeneity (I2 = 90%; p = 0.0001) (see the elec-
tronic supplementary material, Fig. 6E).
4  Discussion
Among the assessed MoAbs, BEVA had been assessed in 
the largest number of studies. The studies on efectiveness 
comparing BEVA and no BEVA groups demonstrated statis-
tically signiicant and clinically relevant beneits in patients 
treated with BEVA principally around OS, PFS, PPS and 
metastasectomy rates, but not in the disease control rate.
With respect to OS, patients given BEVA in combination 
with luoropyrimidine-based CT regimens showed similar 
results across studies; however, better results (outcomes) 
were found when this comparison was made with patients 
who received BEVA versus CETUX. Analysis of the sub-
group of patients given maintenance of treatment with 
BEVA versus no BBP showed patients had better results 
with BEVA + CT compared to those when BEVA was sus-
pended and patients were maintained on CT alone (FOLFIRI 
or FOLFOX) when their disease progressed.
However, the efect on OS, PFS and PPS indicated sig-
niicant heterogeneity, which is probably attributable to dif-
ferences in the efects of BEVA therapy in combination with 
diferent CT regimens. One explanation for these indings 
is that studies tend to be more homogeneous when the same 
combinations of luoropyrimidine-based CT regimens are 
used with each comparator arm. In the sensitivity analysis, 
studies that clearly used BEVA + FOLFOX versus FOLFOX 
(oxaliplatin-based) alone showed high heterogeneity. When 
these studies were excluded from the analysis, we observed a 
reduction in heterogeneity to acceptable levels without alter-
ing the clinical efects for the group.
However, in the PPS subgroup, this diference in timing 
of progression was statistically signiicant, and when the 
study of Grothey et al. [85] was excluded, a reduction of 
heterogeneity to I2 = 0% was observed.
The methodological quality of the various studies was 
moderate, with most studies funded by the pharmaceutical 
industry. This is important since previous meta-analyses 
conducted by our group and others have shown that stud-
ies funded by pharmaceutical companies tend to be more 
positive towards their medicines than those conducted by 
independent groups [57–59].
Fig. 6  Hypertension side efects forest plot
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In addition, high heterogeneity can also be attributed to 
the diferent treatment lines and diferent CT regimens asso-
ciated with anti-angiogenic therapy, anti-epidermal growth 
factor diferences related to the KRAS status (wild type of 
mutation status), diferences in prognostic factors such as 
performance status, location of the primary tumor, and the 
location of the metastases. Declared diferences in COI and 
the quality of the studies can also be considered potential 
sources of heterogeneity. However, in all these cases, a sig-
niicant statistical heterogeneity of I2 > 75% can be expected.
The use of MoAbs as a therapeutic option for mCRC 
created expectations for greater OS, decreased toxicity 
and grade ≥ 3 adverse event complications compared with 
previous cytotoxic CT used in mCRC patients. Notably, it 
was observed that BEVA had been a milestone in clinical 
oncology [91]. However, in reality, there was only a modest 
impact on OS versus current CT regimens.
The results of this meta-analysis point to a statistically 
signiicant advantage in favor of BEVA. This advantage may 
be considered clinically modest in relation to a longer life 
for patients with metastatic disease; however, this should be 
considered a considerable advance in terms of the choices 
and options available for combinations of luoropyrimidine-
based therapeutic regimens. The most important factor to 
note though is a statistically signiicant increase in severe 
adverse events associated with BEVA, especially severe 
hypertension and gastrointestinal perforation, which need 
to be factored into any decision.
Within Brazil, any modest improvement in efectiveness, 
coupled with a signiicant increase in severe adverse events 
with BEVA, needs to be balanced against the increasing 
number of successful litigations as well as the signiicant 
increase in costs and associated expenses with the MoAbs 
(Fig. 1E, electronic supplementary material). This reduces 
available resources for other priority disease areas; however, 
it increases the availability of these MoAb for diseases such 
as mCRC and cervical cancer, among others, which are not 
currently incorporated into the Brazilian health system. This 
raises the need for assessing their comparative efectiveness 
[51, 92] and as a therapeutic alternative capable of being 
incorporated into the Brazilian health system [93].
Our indings should also provide guidance to the judiciary 
when assessing potential funding decisions for these three 
MoAbs in patients with mCRC, similar to the situation with 
insulin glargine [54].
We did not ind any previous systematic reviews assess-
ing the efectiveness and safety of the diferent MoAbs rel-
evant to the current situation. Some randomized studies had 
compared diferent treatment schemes combined or not with 
the MoAbs and showed conlicting results. Some studies 
indicated beneits, whereas others showed an increase in the 
toxicity proile of treatment without impacting on patients’ 
survival [94–99].
The result of this analysis demonstrated that the patients 
prescribed BEVA spend more time without disease pro-
gression and had a higher rate of resection compared to 
the non-BEVA or other anti-EGFR containing regimens, 
and there were signiicant gains in OS when re-analyzed 
to reduce the heterogeneity of the included studies. With 
respect to safety, most studies in the meta-analyses indi-
cated no signiicant reduction in severe adverse events 
using BEVA.
In a meta-analysis of Lv et al. [44], the eicacy and safety 
of adding BEVA to a therapy based on CETUX or PANIT 
for treating patients with mCRC were estimated. The authors 
suggested that the combination of anti-VEGF antibody 
(BEVA) and anti-EGFR antibody (CETUX and PANIT) 
had not improved PFS, OS, or the disease control rate when 
compared with the antibody alone. In addition, the incidence 
of grade ≥ 3 adverse events was not signiicantly greater in 
BEVA groups when compared to CETUX/PANIT groups. 
There are a number of similarities with our study indings.
On the other hand, the meta-analysis conducted by Wag-
ner et al. [47], which compared BEVA versus no BEVA as 
irst-line CT, showed signiicant beneits in OS and PFS in 
patients treated with BEVA. We have previously pointed out 
that in the no BEVA group, in addition to the CT schemes, 
Wagner et al. [47] had used vatalanib (another VEGF inhibi-
tor), which was not included in our review.
We believe this situation justiied the need for additional 
re-evaluation as more data became available. There was a 
high incidence of grade 3 and 4 adverse events for arterial 
hypertension, arterial thromboembolic events and gastroin-
testinal perforations in our review, which may compromise 
patient safety. Observational studies included in this analy-
sis, such as Meyerhardt et al. [88], Grothey et al. [84], and 
Yang et al. [77], agreed with the results found in the RCTs 
indicating the high patient risk of using BEVA. In the meta-
analysis conducted by Hapani et al. [43], the incidence of 
gastrointestinal perforation was 0.9% for patients receiving 
BEVA, with mortality at 21.7%.
Hurwitz et al. [100], comparing various CT schemes, 
combined or not with BEVA, as irst- or second-line treat-
ment, found that the addition of BEVA was associated with 
a signiicant gain in OS and PFS deined by the CT back-
bone (oxaliplatin-based, irinotecan-based) and the extent of 
disease (liver metastases only, extensive disease), which is 
in accordance with the present study. The inclusion of more 
recent studies suggests an increase in OS, especially when 
reducing the heterogeneity of included studies. In addition, 
the incidence of grade ≥ 3 adverse events was higher in the 
group that received combinations with BEVA, conirming 
earlier studies.
With respect to safety, we emphasize that most outcomes 
of meta-analyses indicated no signiicant reduction in severe 
adverse events using BEVA. This implies that the promise 
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to use the MoAbs to reduce adverse events has not yet been 
fulilled [43, 47].
In the studies reviewed and compared in our systematic 
review, there were some diferences compared with individ-
ual studies. Individual studies indicated improvements with 
an average survival duration close to 3 years, and high sur-
vival rates at 5 years, which means an increase of 20% com-
pared to that seen in some trials with patients treated solely 
with CT [101]. However, for most patients, the improvement 
obtained with treatment would be palliative and not cura-
tive [102]. The main expectations are prolonging PPS and 
maintaining quality of life for as long as possible rather than 
improving OS.
It is important to recognize that mCRC is a chronic dis-
ease and that prolonging survival with CT regimens associ-
ated with biological agents is only typically seen for the PPS 
period, although there were modest improvements in OS 
with BEVA. However, it is necessary to evaluate the cost 
of new interventions according to the coniguration of each 
health system and their associated costs for reimbursement 
and funding decisions. Marginal gains for high-cost medi-
cines are not seen as acceptable if this restricts funding for 
other more efective interventions in this and other patient 
populations within health systems with universal access. 
This may well mean denying efective treatment options in 
other high-priority disease areas, which is increasingly dif-
icult to justify within inite budgets [28, 61, 103]. However, 
it is important to note that advances made in irst-line treat-
ment will also be applied to the second-line treatment [4].
In addition, assessments of adverse events have typically 
only been carried out for severe cases. In our review, we did 
not assess the efect that adverse events have on patients’ 
quality of life, i.e., BEVA-induced dysphonia (necrosis of 
the vocal cords) and hearing loss due to BEVA, given that 
they were not life threatening.
Another important inding was the COI seen in some of 
the studies, which Thompson and others [104, 105] con-
sider to be a set of study conditions in which professional 
judgment could be unduly inluenced by interests such as 
inancial gain. Scientiic publications that present a COI with 
pharmaceutical companies can be a concern as they can be 
persuasive and avoid disclosing negative results, more fre-
quently have favorable results towards the sponsor’s medi-
cine, or even inluence the delay in disclosing these results 
as a strategy to protect potential markets [106–110]. Some of 
the indings in the studies selected in this systematic review 
and meta-analysis may have been inluenced by publication 
bias, as shown by funnel plots (see the electronic supplemen-
tary material, Figs. 3E.1 and 4E.2) as well as Fig. 5E, with 
the subgroups combined (COI and no COI) favoring patients 
treated with BEVA (p < 0.00001).
We also performed a meta-analysis to evaluate the quality 
of non-randomized studies, based on the quality assessment 
guideline made by the MOOSE tool, using the Newcastle-
Ottawa scale. Low-quality studies may lead to a distortion of 
the summary of efect estimation (see the electronic supple-
mentary material, Fig. 6E). Our indings show that there is a 
statistically signiicant diference between studies that were 
rated six stars or less and those rated seven stars or higher. 
Consequently, the high heterogeneity among the studies in 
this meta-analysis may be inluenced proportionally by the 
quality of the studies.
We recognize this systematic review has some limita-
tions. We only included observational studies, and the bias 
of this study design is its lack of randomization as well as 
uncontrolled confounding factors. Some studies did not pro-
vide complete and/or accurate information, excluding them 
from the quantitative analysis; consequently, hindering the 
understanding of the heterogeneity found in some compari-
son groups. In addition, only ive studies assessed the efect 
of discontinuing BEVA beyond disease progression, and 
most of the studies did not use the same combinations or 
treatment schemes, although 16 of the 21 studies had used a 
CT scheme combined with luorouracil.
Therapeutic care (in terms of the types of interventions, 
therapeutic schemes, and the level of expertise) was also 
rarely described in detail in these studies.
However, despite these limitations, we believe that our 
indings are robust in view of our methodological approach. 
This was conirmed by the sensitivity analysis where the 
inclusion and exclusion of studies in each comparison did 
not change the direction of most outcomes; however, signii-
cant changes were observed in heterogeneity.
5  Conclusions
The results of this meta-analysis point to a statistically sig-
niicant advantage in favor of BEVA for the outcomes of 
OS, PFS, PPS, and the metastasectomy rate. This advan-
tage may be considered clinically modest in relation to the 
patient’s lifetime in the metastatic stage. This increases the 
choices for combining BEVA with luoropyrimidine-based 
regimens, but we must not overlook the quality of life of 
these patients. This is because one of the most important fac-
tors to be observed with BEVA is the statistically signiicant 
increase in adverse events associated with its use, especially 
severe hypertension and gastrointestinal perforation.
This review also emphasized that studies directly compar-
ing the efectiveness and safety of MoAbs in patients with 
mCRC are currently scarce, which needs to be addressed 
when payers are faced with funding choices. There is also 
a need for further observational studies to assess OS and 
adverse events comparing MoAbs associated with the dif-
ferent CT regimens given current concerns with their impact 
on OS in reality.
 W. C. da Silva et al.
These indings combined with those from RCTs can be 
used to update clinical guidelines to systematically promote 
better and more appropriate healthcare within universal 
healthcare systems through establishing the magnitude 
of beneits, risks, and costs, relating to speciic aspects of 
patient care. In addition, it is hoped this review will also be 
of interest to the judiciary when authorizing resources for 
high-cost medicines with limited beneits, as this means less 
funds are available for valuable medicines in other priority 
areas.
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